
The FDA approved adrabetadex for infantile-onset NPC based on a 55% lower risk of death vs external controls, with a boxed warning for hearing loss.
The call at 3 a.m. on a warm May morning is from the emergency department. The ED physician is seeing a 6-year-old with a seven- to 10-day history of fever as high as 105? F, swollen glands, lethargy, and poor oral intake.






